Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Spanswick, J. Cummings, J. Smyth (1996)
Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.Biochemical pharmacology, 51 12
R. Hunter (1980)
WHO Handbook for Reporting Results of Cancer TreatmentInternational Journal of Radiation Biology, 38
B. Teicher, S. Holden, A. Al-Achi, T. Herman (1990)
Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.Cancer research, 50 11
A Auperin, C Le Pechoux, JP Pignon, C Koning, B Jeremic, G Clamon, L Einhorn, D Ball, MG Trovo, HJ Groen, JA Bonner, T Le Chevalier, R Arriagada (2006)
Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patientsAnn Oncol, 17
FA Shepherd, J Rodrigues Pereira, T Ciuleanu, EH Tan, V Hirsh, S Thongprasert, D Campos, S Maoleekoonpiroj, M Smylie, R Martins, M van Kooten, M Dediu, B Findlay, D Tu, D Johnston, A Bezjak, G Clark, P Santabárbara, L Seymour (2005)
National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancerN Engl J Med, 353
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
D. Parkin (2001)
Global cancer statistics in the year 2000.The Lancet. Oncology, 2 9
A. Babiak, J. Hetzel, F. Goddé, H. König, M. Pietsch, M. Hetzel (2007)
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trialBritish Journal of Cancer, 96
J. Brown (2002)
Tumor Microenvironment and the Response to Anticancer TherapyCancer Biology & Therapy, 1
Parvesh Kumar, James Ii, M. Langer, L. Kohman, A. Elias, F. Kass, W. Eaton, S. Seagren, Mark Green, D. Sugarbaker (1996)
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935Cancer, 77
Mario Castro, Mario Castro, M. Veeder, M. Veeder, J. Mailliard, J. Mailliard, H. Tazelaar, J. Jett, J. Jett (1996)
A prospective study of pulmonary function in patients receiving mitomycin.Chest, 109 4
R. Byhardt, Charles Scott, W. Sause, B. Emami, R. Komaki, Barbara Fisher, Jin Lee, C. Lawton (1998)
Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.International journal of radiation oncology, biology, physics, 42 3
A. Aupérin, C. Péchoux, E. Rolland, W. Curran, K. Furuse, P. Fournel, J. Belderbos, G. Clamon, H. Ulutin, R. Paulus, T. Yamanaka, M. Bozonnat, A. Uitterhoeve, Xiaofei Wang, L. Stewart, R. Arriagada, S. Burdett, J. Pignon (2010)
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 13
A. Aupérin, C. Péchoux, J. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. Trovò, H. Groen, J. Bonner, T. Chevalier, R. Arriagada (2006)
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.Annals of oncology : official journal of the European Society for Medical Oncology, 17 3
V. Spanswick, Jeffrey Cummings, John Smyth (1998)
Current issues in the enzymology of mitomycin C metabolic activation.General pharmacology, 31 4
P. Vaupel, J. Dunst, A. Engert, J. Fandrey, P. Feyer, M. Freund, W. Jelkmann (2005)
Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced AnemiaOncology Research and Treatment, 28
M. Höckel, K. Schlenger, S. Höckel, Billur Aral, U. Schäffer, P. Vaupel (1998)
Tumor hypoxia in pelvic recurrences of cervical cancerInternational Journal of Cancer, 79
A. Jemal, Taylor Murray, Elizabeth Ward, A. Samuels, R. Tiwari, Asma Ghafoor, E. Feuer, M. Thun (2005)
Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 55
N. Hanna, F. Shepherd, F. Fossella, J. Pereira, F. Marinis, J. Pawel, U. Gatzemeier, T. Tsao, M. Pless, T. Muller, H. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, P. Bunn (2004)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
P. Stadler, H. Feldmann, Carolin Creighton, Reinhardt Kau, M. Molls (1998)
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 48 2
T. Berghmans, D. Gourcerol, J. Lafitte, K. Kotsori, M. Paesmans, A. Scherpereel, N. Leclercq, J. Sculier (2008)
Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study.Lung cancer, 61 3
F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes, Susan Coughlin, Yong Kim, J. Bérille (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 10
BACKGROUND: Cisplatin-based chemotherapy in combination with thoracic radiotherapy is frequently used as a standard treatment for patients with unresectable NSCLC stage IIIA/IIIB disease. Within three years up to 70% of these patients develop a disease recurrence and a subgroup relapses within the radiation field. Therapy is challenging for this patient group, since a high degree of tumour hypoxia often makes these tumours resistant to chemotherapy, even if small portions of normoxic regions, in particular in the outer regions of the tumour, might still exist. As Mitomycin is known to be effective under hypoxic conditions, a combination of Mitomycin with Vinorelbine or Cisplatin was used to treat relapses that occur in the radiation field. Simultaneously, erythropoietin was applied to decrease tumour hypoxia. METHODS: Fifteen patients pretreated with definitive radio- or radio-chemotherapy who developed a symptomatic relapse within the radiation field were enrolled in the study: 5 patients with stage IIIB and 10 with stage IV. Patients received Mitomycin 8 mg/m2 on day 1 with either Vinorelbine 25 mg/m2 (in case of Cisplatin pretreatment) on days 1 and 8 or Cisplatin 40 mg/m2 on days 1 and 8 of a 21-day cycle to a maximum of 4 cycles. 40,000 IE Erythropoietin was administered s.c. every 7 days to maintain Hb levels between 12 and 13.0 g/dl. Response (WHO criteria), time to progression, survival, toxicities and Hb values were evaluated. RESULTS: A median of 2 cycles was administered (1–4). Fourteen patients were assessable for clinical response, one died before first tumour response evaluation. One patient achieved a partial response, stable disease was observed in 6 patients. Median time to progression was 2.3 months (95% CI, 1.20–5.60 months) and median survival was 4.6 months (95% CI, 3.42–6.54 months). Main Grade 3/4 toxicities included leucocytopenia (4/15) and neutropenia (4/15). One patient died of a pulmonary fibrosis probably due to Mitomycin medication. Median Hb levels were maintained above 11 g/dl. CONCLUSION: This is the first trial investigating a standardised treatment of pretreated patients with a relapse within the radiation field. The therapeutic concept including Mitomycin for the treatment of recurrent disease in the radiation field offers an active regimen with modest toxicity. Stable disease was observed in 43%, partial response in 7% of the patients and reaches a similar rate as known from chemotherapy results of pretreated patients. Median survival was poor, but may be due to the limited prognosis of this selected patient cohort. There was a trend to better results in patients with performance status 0 or 1 and response to previous radio-chemotherapy. Further studies for patients with radiation field relapses are warranted.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Apr 21, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.